WAVEMAN · COMPANY

TECH · Bio-Techne Corp

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

TECH

Name: BIO-TECHNE Corp (TECH) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

BIO-TECHNE Corp

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0000842023

CONGRESS · 1☆ WATCH

INSIDER NET · 180D

-$320.4K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

293

13F, latest reported quarter

REVENUE GROWTH

-0.4%

XBRL, annual

NET MARGIN

15.0%

CONVERSIONS · 180D

codes C/M, not in net · $9.6M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$320.4K over 180 days

below 52% of Pharma & Biotech

CONGRESS

1 member bought in the last year

the lowest in Pharma & Biotech

FUNDS

293 funds added or opened last quarter

more than 93% of Pharma & Biotech

REVENUE

-0.4% year over year

below 57% of Pharma & Biotech

MARGIN

15.0% net margin

more than 86% of Pharma & Biotech

BUYBACKS

$41.7M repurchased, FY to 2026-06-30

more than 54% of Pharma & Biotech

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

293 funds added or opened positions in the latest 13F quarter, of 598 holders.

1 member of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +36.0%

+36.0%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $320.4K sold by insiders over 180 days, 293 funds added last quarter, 1 Congress member(s) bought in 12 months. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, BIO-TECHNE Corp insiders sold a net $320.4K of stock across 87 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Herr Amy E.

Director

SELL

2026-05-08

6,636.0

$320.4K

Herr Amy E.

Director

SELL

2026-02-17

1,976.0

$116.8K

Nusse Roeland

Director

SELL

2025-08-25

17,040.0

$960.4K

BAUMGARTNER ROBERT V

Director

SELL

2025-08-25

17,040.0

$957.8K

Herr Amy E.

Director

SELL

2025-06-09

1,280.0

$63.7K

87 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 82 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

14,025,816.0 sh

$990.9M

FMR LLC

12,794,784.0 sh

$904.0M

VANGUARD CAPITAL MANAGEMENT LLC

10,218,558.0 sh

$721.9M

GOLDMAN SACHS GROUP INC

7,343,324.0 sh

$518.8M

HBK INVESTMENTS L P

6,825,000.0 sh

$482.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

DF DENT MIDCAP GROWTH FUND

$10.4M POSITION · AS OF 2026-03-31

4.0%

Brown Capital Management Small Company Fund

$11.2M POSITION · AS OF 2026-03-31

3.5%

Global X Genomics & Biotechnology ETF

$1.8M POSITION · AS OF 2026-02-28

3.4%

Mairs & Power Small Cap Fund

$7.8M POSITION · AS OF 2026-03-31

3.4%

Partners III Opportunity Fund

$9.9M POSITION · AS OF 2026-03-31

3.2%

First Trust NYSE Arca Biotechnology Index Fund

$64.2M POSITION · AS OF 2026-03-31

2.8%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2026-06	2025-06	2024-06	2023-06
REVENUE	$1.2B	$1.2B	$1.2B	$1.1B
GROSS PROFIT	$799.1M	$790.3M	$769.7M	$769.8M
OPERATING INCOME	$251.9M	$102.3M	$206.7M	$298.9M
NET INCOME	$181.9M	$73.4M	$168.1M	$285.3M
EPS (DILUTED)	1.16	0.46	1.05	1.76
OPERATING CASH FLOW	$292.1M	$287.6M	$299.0M	$254.4M
CASH	$264.7M	$162.2M	$151.8M	$180.6M
BUYBACKS	$41.7M	$275.7M	$80.0M	$19.6M
DIVIDENDS PAID	$49.9M	$50.4M	$50.4M	$50.3M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE